Avacopan

From Wikipedia, the free encyclopedia

Avacopan
Avacopan.svg
Clinical data
Trade namesTavneos
Other namesCCX168
License data
Routes of
administration		By mouth
Drug classComplement C5a receptor antagonist
ATC code
  • None
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
PDB ligand
Chemical and physical data
FormulaC33H35F4N3O2
Molar mass581.656 g·mol−1
3D model (JSmol)
  • CC1=CC=C(NC(=O)[C@H]2CCCN([C@H]2C2=CC=C(NC3CCCC3)C=C2)C(=O)C2=C(F)C=CC=C2C)C=C1C(F)(F)F
  • InChI=1S/C33H35F4N3O2/c1-20-12-15-25(19-27(20)33(35,36)37)39-31(41)26-10-6-18-40(32(42)29-21(2)7-5-11-28(29)34)30(26)22-13-16-24(17-14-22)38-23-8-3-4-9-23/h5,7,11-17,19,23,26,30,38H,3-4,6,8-10,18H2,1-2H3,(H,39,41)/t26-,30-/m0/s1
  • Key:PUKBOVABABRILL-YZNIXAGQSA-N

Avacopan, sold under the brand name Tavneos, is a medication used to treat anti-neutrophil cytoplasmic autoantibody-associated vasculitis.[1][3]

Avacopan was approved for medical use in Japan in September 2021,[2] and in the United States in October 2021.[1][3] It is the first orally-administered inhibitor of the complement C5a receptor approved by the U.S. Food and Drug Administration (FDA).[3]

Society and culture[]

Legal status[]

In November 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Tavneos, intended, in combination with a rituximab or cyclophosphamide regimen, for the treatment of adults with severe, active granulomatosis with polyangiitis or microscopic polyangiitis.[4] The applicant for this medicinal product is Vifor Fresenius Medical Care Renal Pharma France.[4] The EMA considers avacopan to be a first-in-class medicine.[5]

Names[]

Avacopan is the international nonproprietary name (INN).[6]

References[]

  1. ^ a b c "Tavneos- avacopan capsule". DailyMed. Retrieved 31 October 2021.
  2. ^ a b "ChemoCentryx Announces Approval in Japan of Tavneos (Avacopan) for the Treatment of ANCA-Associated Vasculitis". ChemoCentryx, Inc. (Press release). 27 September 2021. Retrieved 11 October 2021.
  3. ^ a b c "ChemoCentryx Announces FDA Approval of Tavneos (avacopan) in ANCA-Associated Vasculitis". ChemoCentryx, Inc. (Press release). 8 October 2021. Retrieved 11 October 2021.
  4. ^ a b "Tavneos: Pending EC decision". European Medicines Agency. 11 November 2021. Retrieved 12 November 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  5. ^ "First-in-class medicine recommended for treatment of rare blood vessel inflammation". European Medicines Agency (Press release). 12 November 2021. Retrieved 12 November 2021.
  6. ^ World Health Organization (2016). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 76". WHO Drug Information. 30 (3). hdl:10665/331020.

Further reading[]

External links[]

  • "Avacopan". Drug Information Portal. U.S. National Library of Medicine.
  • Clinical trial number NCT02994927 for "A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis (ADVOCATE)" at ClinicalTrials.gov


Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by .

  • v
  • t
Retrieved from ""